$432 Million is the total value of COMMODORE CAPITAL LP's 25 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CCCC | C4 THERAPEUTICS INC | $15,491,000 | -27.9% | 481,094 | 0.0% | 3.59% | -36.7% | |
CELC | CELCUITY INC | $12,141,000 | -26.7% | 920,464 | 0.0% | 2.81% | -35.6% | |
TENAYA THERAPEUTICS INC | $9,739,000 | -8.2% | 513,930 | 0.0% | 2.26% | -19.4% | ||
KALV | KALVISTA PHARMACEUTICALS INC | $4,135,000 | -24.2% | 312,553 | 0.0% | 0.96% | -33.4% | |
KRON | KRONOS BIO INC | $4,061,000 | -35.2% | 298,839 | 0.0% | 0.94% | -43.0% | |
DYN | DYNE THERAPEUTICS INC | $3,628,000 | -26.8% | 305,125 | 0.0% | 0.84% | -35.7% | |
IVA | INVENTIVA SAads | $3,588,000 | -3.5% | 262,658 | 0.0% | 0.83% | -15.3% | |
GNCA | GENOCEA BIOSCIENCES INC | $3,573,000 | -39.6% | 3,079,756 | 0.0% | 0.83% | -46.9% | |
PMVP | PMV PHARMACEUTICALS INC | $2,888,000 | -22.5% | 125,000 | 0.0% | 0.67% | -31.9% | |
BLSA | BCLS ACQUISITION CORP | $2,450,000 | -1.6% | 250,000 | 0.0% | 0.57% | -13.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
CELCUITY INC | 10 | Q3 2023 | 7.3% |
KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-04-19 |
SC 13G | 2024-03-21 |
13F-HR/A | 2024-02-14 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.